High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Phase 2 Unknown 30 enrolled Betta Pharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This trail is designed to assess the efficacy and safety of high dose Iconitib combined with SRS for NSCLC patients harboring EGFR mutation with brain metastases.

Timeline

Start: 2016-03
Primary completion: 2021-12
Completion: 2022-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Icotinib	Small molecule	375 mg	—

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Summary

Timeline

Drugs

Indications